RANDAL J KIRK
CIK 1091823 · Executive Chairman · last filed 2026-03-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$22.31M
Companies
12
Total Filings
224
Lifetime Open-Market Net
$457.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | Director | 477,492 | $4.45 | $2.12M | $42.06M | 40 | 2026-03-16 |
| AQB | 10%+ Owner | 7,493 | $1.00 | $7.5K | $714.5K | 11 | 2021-11-24 |
| PRECIGEN, INC. (XON) Delisted | Executive Chairman | 176,628 | — | — | $206.60M | 80 | 2020-01-07 |
| Theriva Biologics, Inc. (SYN) Delisted | 10%+ Owner | 234,493 | $1.02 | $239.2K | $20.80M | 4 | 2019-04-03 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 3,601,994 | $0.87 | $3.12M | $43.29M | 20 | 2018-10-09 |
| PRPO | 10%+ Owner | 506,657 | $22.10 | $11.20M | -$10.1K | 3 | 2018-08-30 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | 10%+ Owner | 3,917,041 | — | — | $39.79M | 39 | 2018-08-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 6,400,783 | — | — | $41.32M | 4 | 2017-03-10 |
| OGEN | 10%+ Owner | 14,481,089 | $0.62 | $8.98M | $8.55M | 3 | 2016-07-05 |
| TBIO | 10%+ Owner | 3,020,267 | $0.00 | $302 | $4.47M | 5 | 2016-01-11 |
| CLINICAL DATA INC (CLDA) Delisted | Director | 0 | — | — | $49.60M | 10 | 2011-04-12 |
| NEW RIVER PHARMACEUTICALS INC (NRPH) Delisted | Chairman, President and CEO | — | — | — | $0 | 1 | 2007-01-31 |
Recent Filings · Page 2 of 23
224 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-18 | PGEN | Grant (A) | +69,930 | $100.0K | EDGAR |
| 2024-03-12 | PGEN | Exer (M) | +213,675 | $0 | EDGAR |
| 2023-12-29 | PGEN | Buy (P) | +96,686 | $136.3K | EDGAR |
| 2023-08-17 | PGEN | Buy (P) | +500,000 | $757.6K | EDGAR |
| 2023-08-17 | PGEN | — | — | $0 | EDGAR |
| 2023-03-13 | PGEN | Grant (A) | +85,470 | $100.0K | EDGAR |
| 2023-02-24 | PGEN | Exer (M) | +123,152 | $0 | EDGAR |
| 2023-01-31 | PGEN | Buy (P) | +11,428,571 | $20.00M | EDGAR |
| 2023-01-06 | PGEN | Exer (M) | +3,443 | $0 | EDGAR |
| 2022-10-07 | PGEN | Other (J) | +1,054,463 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.